Market research
136.F Adamas Pharmaceuticals, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 335M
- P/E ratio
- Not available
- Analyst target
- 8.79
- Dividend yield
- Not available
- Beta
- 2.68
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- Not available
- Market cap
- 335M
- P/E ratio
- Not available
- Analyst target
- 8.79
- Dividend yield
- Not available
- Beta
- 2.68
About
About Adamas Pharmaceuticals, Inc
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. As of November 24, 2021, Adamas Pharmaceuticals, Inc. operates as a subsidiary of Supernus Pharmaceuticals, Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 136.F discussion.
5 years, 5 months ago
Adamas Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 14.5% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.8.
Adamas Pharmaceuticals, Inc's total revenue rose by 28.5% to $21M since the same quarter in the previous year.
Its net income has increased by 20.8% to $-18M since the same quarter in the previous year.
Finally, its free cash flow grew by 43.6% to $-10M since the same quarter in the previous year.
Based on the above factors, Adamas Pharmaceuticals, Inc gets an overall score of 5/5.